Identifying early markers of alzheimer's disease using quantitative multiplex proteomic immunoassay panels

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 56-67

  Soares, Holly D ^a   Chen, Yu ^a   Sabbagh, Marwin ^b   Rohrer, Alex ^b   Schrijvers, Elisabeth ^c   Breteler, Monique ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; Biomarkers; Luminex; Plasma

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANGIOPOIETIN 2; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; FLUORODEOXYGLUCOSE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RANTES; SOMATOMEDIN BINDING PROTEIN 6; TAU PROTEIN; THREONINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; IMMUNOASSAY; MULTIVARIATE ANALYSIS; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ASSAY; REPRODUCIBILITY; SCREENING; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOASSAY; MALE; PROTEOMICS;

EID: 70449435231     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05066.x     Document Type: Conference Paper

References (48)

1. Brookmeyer, R., E. Johnson, D. Ziegler-Grahamm, et al. 2007. Forecasting the global prevalence and burden of Alzheimer's disease. Alzheimers Dement. 3: S168.
2. Ikonomovic, M.D., W.E. Klunk, E.E. Abrahamson, et al. 2008. Post-mortem correlates of in vivo PiBPET amyloid imaging in a typical case of Alzheimer's disease. Brain 131: 1630-1645.
3. Thal, D.R., U. Rub, M. Orantes, et al. 2002. Phases of A beta-deposition in the human brain and its relevance for the development ofAD. Neurology 58: 1791-1800.
4. Villemagne, V.L., K.E. Pike, D. Darby, et al. 2008. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46: 1688-1697.
5. Dubois, B., H.H. Feldman, C. Jacova, et al. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6: 734-746.
6. Jagust,W., A. Gitcho, F. Sun, et al. 2006. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann. Neurol. 59: 673-681.
7. Langbaum, J.B., K. Chen, W. Lee, et al. 2009. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images fromthe Alzheimer'sDisease Neuroimaging Initiative (ADNI). Neuroimage 45: 1107-1116.
8. Drzezga, A., T.Grimmer, M. Riemenschneider, et al. 2005. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 46: 1625-1632.
9. Mathis, C.A., W.E. Klunk, J.C. Price, et al. 2005. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch. Neurol. 62: 196-200.
10. Andreasen, N., E. Vanmechelen, H. Vanderstichele, et al. 2003. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol. Scand. Suppl. 179: 47-51.
11. Hampel, H., S.J. Teipel, T. Fuchsberger, et al. 2004. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 9: 705-710.
12. Hansson, O., H. Zetterberg, P. Buchhave, et al. 2006. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5: 228-234.
13. Lewczuk, P., J. Kornhuber, O. Vanmechelen, et al. 2009. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp. Neurol. PMID: 19664622. E-pub ahead of print August 5, 2009.
14. Herukka, S.K., S. Helisalmi, M. Hallikainen, et al. 2007. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging 28: 507-514.
15. Mattsson, N., H. Zetterberg, O. Hansson, et al. 2009. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Jama 302: 385-393.
16. Schoonenboom, S.N., P.J. Visser, C. Mulder, et al. 2005. Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 11: 8-13.
17. Shaw, L.M., H. Vanderstichele, M. Knapik-Czajka, et al. 2009. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65: 403-413.
18. Visser, P.J., F. Verhey, D.L. Knol, et al. 2009. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patientswith subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8: 619-627.
19. Zetterberg, H., L.O. Wahlund & K. Blennow. 2003. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 352: 67-69.
20. Snider, B.J., A.M. Fagan, C. Roe, et al. 2009. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch. Neurol. 66: 638-645.
21. Hampel, H., K. Buerger, R. Zinkowski, et al. 2004. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch.Gen. Psychiatry 61: 95-102.
22. Fagan, A.M., M.A. Mintun, R.H. Mach, et al. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59: 512-519.
23. Forsberg, A., H. Engler, O. Almkvist, et al. 2008. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29: 1456-1465.
24. Frisoni, G.B., A. Prestia, O. Zanetti, et al. 2009. Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement. 5: 307-317.
25. Weiner, M.W. 2009. Editorial: imaging and biomarkers will be used for detection andmonitoring progression of early Alzheimer's disease. J. Nutr. Health Aging 13: 332.
26. Jack, C.R., Jr., M.M. Shiung, S.D. Weigand, et al. 2005. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65: 1227-1231.
27. Stoub, T.R., M. Bulgakova, S. Leurgans, et al. 2005. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 64: 1520-1524.
28. Stoub, T.R., E.J. Rogalski, S. Leurgans, et al. 2008. Rate of entorhinal and hippocampal atrophy in incipient and mild AD: Relation to memory function. Neurobiol. Aging. doi:10.1016/j.neurobiolaging.2008. 08.003. E-pub ahead of print September 21, 2008.
29. Vemuri, P., J.L. Gunter, M.L. Senjem, et al. 2008. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 39: 1186-1197.
30. Vemuri, P., J.L. Whitwell, K. Kantarci, et al. 2008. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 42: 559-567.
31. Muller, M.J., D. Greverus, C. Weibrich, et al. 2007. Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol. Aging 28: 398-403.
32. Jungwirth, S., S. Zehetmayer, P. Bauer, et al. 2009. Screening for Alzheimer's dementia at age 78 with short psychometric instruments. Int. Psychogeriatr. 21: 548-559.
33. Jackson, C.E. & P.J. Snyder. 2008. Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease. Alzheimers Dement. 4(1 Suppl 1): S137-S143.
34. Sjobeck, M., M. Haglund & E. Englund, 2005. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease-a neuropathological study. Int. J. Geriatr. Psychiatry 20: 919-926.
35. Skoch, J., A. Dunn, B.T. Hyman, et al. 2005. Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology. J. Biomed. Opt. 10: 11007.
36. Kier, F.J. & V. Molinari. 2003. "Do-it-yourself" dementia testing: issues regarding an Alzheimer's home screening test. Gerontologist 43: 295-301.
37. Hye, A., S. Lynham, M. Thambisetty, et al. 2006. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11): 3042-3050.
38. Ray, S., M. Britschgi, C. Herbert, et al. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13: 1359-1362.
39. German, D.C., P. Gurnani, A. Nandi, et al. 2007. Serum biomarkers forAlzheimer's disease: proteomic discovery. Biomed. Pharmacother. 61: 383-389.
40. Sheta, E.A., S.H. Appel & I.L. Goldknopf. 2006. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Exp. Rev. Proteomics 3: 45-62.
41. Zhang, R., L. Barker, D. Pinchev, et al. 2004. Mining biomarkers in human sera using proteomic tools. Exp. Rev. Proteomics 4: 244-256.
42. FDA. 2001. Guidance for the Industry: Bioanalytical Method Validation. FDA, CDER and CVM. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCMO70107. pdf.
43. Tusher, V.G., R. Tibshirani & G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98: 5116-5121.
44. Gomez Ravetti, M. & P. Moscato. 2008. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS One 3: e3111.
45. Smith, J.D. 2000. Apolipoprotein E4: an allele associated with many diseases. Ann. Med. 32: 118-127.
46. Hofman, A., M.M. Breteler, C.M. Van Duijn, et al. 2007. The Rotterdam Study: objectives and design update. Eur. J. Epidemiol. 22: 819-829.
47. Schrijvers, E., H. Soares, A. Hofman, et al. 2009. Prediction of Alzheimer's disease by means of a biomarker profile in the Rotterdam Study O3-04-101 ICAD, Vienna.
48. Van Oijen, M., A. Hofman, H.D. Soares, et al. 2006. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5: 655-660.